NCT06393140 The Study on the Mechanism of Radiotherapy-elicited Immune Response
| NCT ID | NCT06393140 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fudan University |
| Condition | Esophageal Carcinoma Salivary Gland Type |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2022-07-01 |
| Primary Completion | 2026-07-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2022-07-01 with a primary completion date of 2026-07-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Radiotherapy plays an important role in multidisciplinary treatment of esophageal cancer. Data from many laboratories indicate that local radiation produces systemic, immune-mediated anti¬tumour and, potentially, antimetastatic effects. Additionally, the combination of local radiotherapy and immune-modulation can augment local tumour control and cause distant (abscopal) antitumour effects through increased tumour-antigen release and antigen-presenting cell (APC) cross-presentation, improved dendritic-cell (DC) function, and enhanced T cell priming. The generation of an effective antitumor immune response requires the presentation of tumor antigens to naïve CD8+ cells in tumor-draining lymph nodes (TDLN) . Tumor-draining lymph nodes, however, are often subject to the immunosuppressive activity of tumor-derived factors, such as cytokines and other bioactive molecules from tumor cells and their associated leukocytes in the primary tumor site that contribute to the overriding of effective rejection mechanisms. Thus, in TDLN a T cell tolerance rather than a T cell activation often occurs, thereby preventing immune attack and facilitating local tumor progression.
Eligibility Criteria
Inclusion Criteria: 1. new diagnosis locoregional esophageal cancer; 2. pathologic diagnosis is squamous carcinoma; 3. Patients had received either neoadjuvant or definitive radiotherapy 4. tumor and lymph node tissue can be collected and can be conducted with single cell RNA (scRNA)-sequencing and other sequencings. Exclusion Criteria: 1. Pregnant or lactating women. 2. Unable or rejection to receive radiotherapy or unable to comply with study requirements or follow-up schedule. 3. Inability to provide informed consent.
Contact & Investigator
Kuaile Zhao, MD
STUDY DIRECTOR
Fudan University
Frequently Asked Questions
Who can join the NCT06393140 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Esophageal Carcinoma Salivary Gland Type. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06393140 currently recruiting?
Yes, NCT06393140 is actively recruiting participants. Contact the research team at kuaile_z@sina.com for enrollment information.
Where is the NCT06393140 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06393140 clinical trial?
NCT06393140 is sponsored by Fudan University. The principal investigator is Kuaile Zhao, MD at Fudan University. The trial plans to enroll 200 participants.